VCD-D Study (AMaRC 16-03)
A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.
The primary purpose of this trial is to assess whether the addition of datatumumab to a velcade, cyclophosphamide and dexamethasone treatment regime will cause an improvement in disease progression free survival.
For more information please visit
Project Information
Institution:
Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)
Specialities:
Haematology
Oncology
Other (specify below)
End date:
​
Can this be done remotely?
​
Suitability:
​
Parts of research done:
Literature review, Research proposal, Ethics approval
Positions Available:
Data Collector
Statistician
​
Current Funding:
Janssen
​
Prospective researchers receive:
​
Website
​
Project owner
Peter Mollee